# Terrestrial Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/terrestrial-bio

- Industry: Pharmaceuticals
- Headquarters: Woburn, US
- Website: www.terrestrialbio.com
- Total disclosed funding: $124M
- Latest round: Series C (Mar 26, 2026)
- Investors on record: 7

## About

Founded in 2012 by Kathryn Kosuda (CSO) and Livio Valenti, and based in Massachusetts, US, Vaxess Technologies, Inc. is a life science company that develops technologies based on a silk biopolymer platform for the delivery of vaccines and therapeutics.  In March 2026, Terrestrial Bio, Inc. raised USD 50 million in series C funding led by RA Capital Management, with participation from Engine Ventures, Global Health Investment Advisors, and SiteGround. As of 2024, the company is being led by its CEO, Rachel Sha.  Vaxess Technologies Inc. is developing advanced delivery systems for vaccines and therapeutics using its MIMIX™ platform, which employs silk fibroin biomaterials. This technology enables needle-free, refrigeration-free administration, allowing self-administration at home or in low-resource settings. The MIMIX™ patch uses a microarray of bioactive tips to gradually release medications after application.  

The company will use the March 2026 funding to expand manufacturing capabilities, establish a new headquarters in Boston, and advance clinical trials and commercialization of its lead GLP-1 program.

## Funding rounds

- Series C, Mar 26, 2026, $50M — RA Capital Management, Engine Ventures, Global Health Investment Advisors, SiteGround
- Series B, Jul 17, 2023, $9.1M — Ulu Ventures, RA Capital Management, Engine Ventures, Global Health Investment Advisors
- Series B, Apr 29, 2021, $25M — RA Capital Management, Mission Biocapital, Engine Ventures
- Series B, Apr 29, 2021, $35M — RA Capital Management, Mission Biocapital, Engine Ventures
- Series A, Jun 27, 2019, $3.6M — Mission Biocapital, Engine Ventures
- Series A, May 29, 2013, $1.3M — Norwich Ventures

## Investors

- Norwich Ventures (https://capitalatlas.ai/funds/norwich-ventures) — Series A
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A, Series B
- Engine Ventures (https://capitalatlas.ai/funds/engine-ventures) — Series A, Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Ulu Ventures (https://capitalatlas.ai/funds/ulu-ventures) — Series B
- Global Health Investment Advisors — Series B, Series C
- SiteGround — Series C